Please assess the completion status of the following clinical trial:

Trial Title: Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of malignant solid cancer, ECOG 0-2.~* Disease progression on established treatments or patients not eligible to standard options.~* Signed informed consent must be obtained.~Exclusion Criteria:~* Pregnancy.~* Life expectancy less than 3 months.~* Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures.~* Patients with severe systemic autoimmune disease.~* Patients that do not consent to that tissue and blood samples are stored in a biobank.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AdCD40L (Type: EXPERIMENTAL): Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).